Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide in Hypercholesterolemia
NCT06450366Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of enlicitide in hypercholesterolemia (4 arms), sponsored by Merck & Co. Primary endpoint: Mean Percent Change From Baseline in Low-density Lipoprotein Cholesterol at 8 weeks. Started Jul 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06450366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06450366.